The project team at ACCELLENA has announced the completion of patient enrollment in a Phase III clinical trial evaluating the efficacy and safety of an investigational drug for the treatment of non-organic insomnia in adult patients. The trial is sponsored by Evalar CJSC.
A total of 261 patients were enrolled across eight clinical sites in the Russian Federation. Recruitment was completed within three months, thanks to high professionalism and well-coordinated efforts of the clinical sites and the project team.
ACCELLENA is fully responsible for the organization and management of the trial. The team handles medical writing, logistics, interaction with ethics committees, clinical sites support, staff training, monitoring visits, data management, biostatistics and preparation of a final report.
The completion of patient enrollment marks an important milestone in the study and a significant step toward developing new effective therapies for insomnia. The next stage involves data analysis, which will assess the drug's clinical profile and its potential role in modern medical practice.
A total of 261 patients were enrolled across eight clinical sites in the Russian Federation. Recruitment was completed within three months, thanks to high professionalism and well-coordinated efforts of the clinical sites and the project team.
ACCELLENA is fully responsible for the organization and management of the trial. The team handles medical writing, logistics, interaction with ethics committees, clinical sites support, staff training, monitoring visits, data management, biostatistics and preparation of a final report.
The completion of patient enrollment marks an important milestone in the study and a significant step toward developing new effective therapies for insomnia. The next stage involves data analysis, which will assess the drug's clinical profile and its potential role in modern medical practice.
